Clinical Trial: The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE.

U.S., Sept. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07844200) titled 'The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE.' on Aug. 27.

Brief Summary: The primary objective of the trial is to evaluate the effect of the addition of belantamab mafodotin to standard of care therapy on the titres of serum anti-dsDNA antibodies in patients with previously treated SLE. Estimand for Primary Endpoint: Change of serum anti-dsDNA antibody titers at 24 weeks of treatment vs baseline.

Study Start Date: Feb., 2027

Study Type: INTERVENTIONAL

Condition:...